Lavirk (Aciclovir)

Aciclovir is taken up by virus‑infected cells and phosphorylated by viral thymidine kinase to a monophosphate, then to the active triphosphate by cellular enzymes. The triphosphate competitively inhibits viral DNA polymerase, halting DNA chain elongation and preventing the virus from replicating.

The dosing regimen for Lavirk is determined by the prescribing clinician based on the type, location and severity of the herpes lesion. Typical regimens involve applying a thin layer to the affected area several times daily for a prescribed number of days, but exact instructions must come from a qualified healthcare professional.

Data on topical aciclovir use during pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Lavirk to pregnant or breastfeeding individuals. Consultation with a medical professional is essential.

To order Lavirk, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lavirk (aciclovir) and alternative topical antivirals such as penciclovir share a similar mechanism of inhibiting viral DNA synthesis. Aciclovir has a well‑established safety profile and is effective for a broad range of herpes lesions, while penciclovir may offer slightly longer intracellular retention. Choice depends on clinical judgment, lesion type and patient tolerance.

Store Lavirk at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat. Keep the container tightly closed when not in use to maintain stability and potency.

Lavirk is applied topically to clean, dry skin. Use a thin layer over the affected area, typically 5 minutes before bedtime and again in the morning, unless otherwise directed by a healthcare professional. Wash hands before and after application to avoid accidental spread to other body sites.

Serious adverse reactions are rare but may include allergic contact dermatitis, Stevens‑Johnson syndrome, or severe ocular irritation if used incorrectly. Any signs of widespread rash, blistering, swelling, or vision changes require immediate medical attention and discontinuation of the product.

Lavirk should be avoided in individuals with a known hypersensitivity to aciclovir or any component of the formulation. It is also contraindicated for use on healthy, non‑infected skin, and ocular application should be limited to the ophthalmic version of the product.